

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VOLUNTARY ANNOUNCEMENT IN RELATION TO THE PROPOSED DISPOSAL OF THE EQUITY INTERESTS IN NT PHARMA (OVERSEAS) HOLDING CO., LTD**

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

### **I. BACKGROUND**

Reference is made to the voluntary announcement of the Company dated 12 May 2025 in relation to the proposal by Beijing Kangchen Pharmaceutical Co., Ltd. to split the assets of Beijing Kangchen Biotech Co., Ltd. (“**Beijing Kangchen Biotech**”) and dissolve the associate relationship. Since the said announcement, the above asset split plan has not made further progress.

In order to alleviate the liquidity strain of the Group and to meet the needs of its strategic transformation, the Company proposes to dispose of part or all of its equity interests in NT Pharma (Overseas) Holding Co., Ltd (“**NT Overseas**”) (the “**Proposed Disposal**”). NT Overseas is an indirect wholly-owned subsidiary of the Company (held through NT Pharma (Group) Co., Ltd.), and through its direct wholly-owned subsidiary, NT Pharma (Asia) Company Limited, it indirectly holds 25.30% equity interests in Beijing Kangchen Biotech.

### **II. LATEST DEVELOPMENTS**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders of the Company and potential investors that the Company has made initial contacts with potential interested purchasers in respect of the Proposed Disposal. As at the date of this announcement, the matter is still at a very preliminary stage of directional discussion, and no substantive plan or specific terms have been formed, nor has any legally binding agreement or memorandum of understanding been entered into.

This announcement merely expresses the Company's intention to dispose of the equity interests subject to the Proposed Disposal and does not constitute any legally binding offer, undertaking or agreement to any person, and there is no assurance that any transaction will be materialised.

### **III. UNCERTAINTIES AND COMPLIANCE ARRANGEMENTS**

Shareholders and potential investors should note that the disposal of the Proposed Disposal is still at a very preliminary stage of directional discussion. There is no assurance that any transaction will be materialised or completed. Even if the transaction is materialised, there remains significant uncertainty in respect of its terms and conditions and the timeline for completion. The consummation of any final transaction will be subject to, among others, the results of due diligence, the buyer's offer, regulatory approvals (if applicable), and the negotiation and execution of formal transaction documents. The final consideration for the Proposed Disposal will be determined by the Company and the relevant purchaser through fair negotiation with reference to the results of due diligence.

The Company will continue to assess the developments, and in the event of clear progress in the relevant discussions (including, but not limited to, obtaining a substantive offer, signing a letter of intent, or terminating the intention), the Company will comply with the relevant compliance procedures in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and will issue a further announcement in due course where appropriate.

Shareholders and potential investors are advised to exercise extreme caution when dealing in the shares of the Company and, if in any doubt, should seek independent advice from professional or financial advisers.

By order of the Board  
**China NT Pharma Group Company Limited**  
*Chairman*  
**Ng Tit**

Hong Kong, 29 May 2026

*As at the date of this announcement, the executive directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.*